The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status—Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).
 
Samuel A. Jacobs
No Relationships to Disclose
 
James J. Lee
Consulting or Advisory Role - Incyte; Loxo
Research Funding - Incyte; Merck
 
Thomas J. George
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst)
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
Tatjana Kolevska
No Relationships to Disclose
 
Kathleen J Yost
Other Relationship - Pfizer
 
James Lloyd Wade
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Abbott (I); Celgene; GlaxoSmithKline (I); Johnson & Johnson (I); Novartis (I); Seagen
 
Gary L Buchschacher
No Relationships to Disclose
 
Philip J. Stella
No Relationships to Disclose
 
Asheesh Shipstone
No Relationships to Disclose
 
Katherine L. Pogue-Geile
Patents, Royalties, Other Intellectual Property - The following patent was submitted: U. S. Patent Application Serial No. 14/738,757, entitled: “Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin." Published 12/24/15.
 
Ashok Srinivasan
No Relationships to Disclose
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Bayer (I)
 
Carmen Joseph Allegra
No Relationships to Disclose